SBI-553 is a novel compound that reduces feeing and alters cell signaling Receptor expression in the 4 major breast cancer subtypes Progression of primary biliary cholangitis Mechanism of the antibody-drug conjugate, Datroway Cellular mechanisms of idiopathic pulmonary fibrosis
